

**AMENDMENTS TO THE CLAIMS:**

*This listing of claims will replace all prior versions, and listings, of claims in the application.*

**LISTING OF CLAIMS:**

Claims 1-54 (Canceled)

Claim 55 (Previously Presented): A process for treating biological targets in a fluid of a biological organism, comprising introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber for conveying a flow of the fluid, and a capture zone comprising a target-specific binding agent,

wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent.

Claim 56 (New): The process of claim 55, wherein the assembly is implanted in a body.

Claim 57 (New): The process of claim 55, wherein the assembly is present outside of a body.

Claim 58 (New): The process of claim 55, wherein the fluid comprises blood, bone marrow, lymph, urine, bile, cerebral spinal fluid or a combination thereof.

Claim 59 (New): The process of claim 55, wherein the fluid introduced to the assembly is an enriched fluid.

Claim 60 (New): The process of claim 55, wherein the biological target comprises a metastatic cancer cell, a stem cell or an immunological cell.

Claim 61 (New): The process of claim 55, wherein the assembly comprises a stent, catheter, cannula, capsule, patch, wire, infusion sleeve, fiber, shunt or graft.

Claim 62 (New): The process of claim 55, wherein the assembly is formed from a natural or synthetic polymer, fiber, diatomaceous earth, glass, metal, colloid or plastic.

Claim 63 (New): The process of claim 55, wherein the target-specific binding agent comprises E-selectin, P-selectin, ICAM-1, cadherin-11 or a combination thereof.

Claim 64 (New): The process of claim 55, wherein the target-specific binding agent is immobilized to a surface of the capture zone.

Claim 65 (New): The process of claim 55, wherein after flux rolling of the biological target along the target-specific binding agent, the biological target is removed from the capture zone.

Claim 66 (New): The process of claim 55, wherein after flux rolling of the biological target along the target-specific binding agent, the biological target is reintroduced to the fluid of the biological organism.

Claim 67 (New): The process of claim 55, wherein the biological target passes through the assembly at least twice.

Claim 68 (New): The process of claim 55, wherein the target-specific binding agent is adsorbed or covalently bonded to a surface of the capture zone.

Claim 69 (New): The process of claim 55, wherein the capture zone further comprises an anti-proliferative agent, a toxic agent, a bio-active agent or a combination thereof, for neutralizing the biological target.

Claim 70 (New): The process of claim 69, wherein the anti-proliferative agent, toxic agent, bio-active agent or combination thereof is adsorbed or covalently bonded to a surface of the capture zone.